Skip to content

PROVECTUS BIOPHARMACEUTICALS, INC.: 10-Q filed 2014-05-08

What PROVECTUS BIOPHARMACEUTICALS, INC. reported in its quarterly report filed 2014-05-08 (fiscal Q1 2014): 26 published measures, 86 facts as tagged in accession 0001193125-14-188810.

This filing

Form
10-Q (quarterly report)
Filed
2014-05-08
Fiscal period
fiscal Q1 2014
Accession
0001193125-14-188810 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PROVECTUS BIOPHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2014-03-3120,791,361USD
At 2013-12-3120,008,184USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2014-03-316,271,210USD
At 2013-12-3113,379,518USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2014-03-3114,520,151USD
At 2013-12-316,628,666USD
At 2012-12-314,393,484USD
At 2011-12-3110,019,740USD
At 2010-12-3110,699,573USD
At 2009-12-319,406,510USD
At 2008-12-3110,055,536USD
At 2007-12-3114,831,510USD
At 2006-12-3115,522,400USD
At 2005-12-3114,387,141USD
At 2004-12-319,161,701USD
At 2003-12-3110,251,052USD
At 2002-12-3111,723,580USD
At 2002-04-23802USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2014-03-3116,648,916USD
At 2013-12-3115,696,243USD
At 2013-03-314,318,150USD
At 2012-12-311,221,701USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2014-01-01 to 2014-03-31-6,667,267USD90
2002-02-01 to 2014-03-31-152,718,087USD4442
2002-01-18 to 2014-03-31-152,718,087USD4456
2013-01-01 to 2013-12-31-27,697,744USD365
2013-01-01 to 2013-03-31-4,170,182USD90
2012-01-01 to 2012-12-31-12,568,354USD366
2011-01-01 to 2011-12-31-19,434,699USD365
2010-01-01 to 2010-12-31-18,552,102USD365
2009-01-01 to 2009-12-31-12,322,314USD365
2008-01-01 to 2008-12-31-10,269,571USD366
2007-01-01 to 2007-12-31-10,005,631USD365
2006-01-01 to 2006-12-31-8,870,579USD365
2005-01-01 to 2005-12-31-11,763,853USD365
2004-01-01 to 2004-12-31-4,344,525USD366
2003-01-01 to 2003-12-31-3,155,313USD365
2002-04-24 to 2002-12-31-5,749,937USD252
2002-01-18 to 2002-04-23-1,316,198USD96

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2014-01-01 to 2014-03-31-2,850,713USD90
2002-02-01 to 2014-03-31-88,757,805USD4442
2013-01-01 to 2013-03-31-2,976,420USD90

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2002-02-01 to 2014-03-3196,570USD4442

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2014-01-01 to 2014-03-313,803,386USD90
2002-02-01 to 2014-03-31104,949,921USD4442
2013-01-01 to 2013-03-316,072,869USD90

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2002-02-01 to 2014-03-31456,800USD4442

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2014-03-31-152,718,087USD
At 2013-12-31-146,050,820USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2014-03-3128,397USD
At 2013-12-3130,113USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2014-01-01 to 2014-03-31-4,381,607USD90
2002-01-18 to 2014-03-31-133,459,244USD4456
2013-01-01 to 2013-03-31-3,246,699USD90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2014-03-3116,648,916USD
At 2013-12-3115,696,243USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2014-03-31835,154USD
At 2013-12-31512,946USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2014-03-314,087,048USD
At 2013-12-314,254,828USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2002-02-01 to 2014-03-3148,000USD4442

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2002-01-18 to 2014-03-3124,541USD4456

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2014-01-01 to 2014-03-311,157,883USD90
2002-01-18 to 2014-03-3147,852,291USD4456
2013-01-01 to 2013-03-31740,516USD90

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2014-03-31173,125,972shares
At 2013-12-31159,751,724shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2014-03-31167,065,112USD
At 2013-12-31152,519,701USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2014-03-31431,047USD
At 2013-12-31429,331USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2014-03-3127,000USD
At 2013-12-3127,000USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2014-01-01 to 2014-03-31-6,667,267USD90
2002-01-18 to 2014-03-31-164,744,797USD4456
2013-01-01 to 2013-03-31-5,247,116USD90

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2014-01-01 to 2014-03-313,055,944USD90
2002-01-18 to 2014-03-3178,003,097USD4456
2013-01-01 to 2013-03-312,338,403USD90

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2014-01-01 to 2014-03-311,716USD90
2002-02-01 to 2014-03-31454,048USD4442
2013-01-01 to 2013-03-311,550USD90

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2014-01-01 to 2014-03-31167,780USD90
2002-02-01 to 2014-03-317,628,397USD4442
2002-01-18 to 2014-03-317,628,397USD4456
2013-01-01 to 2013-03-31167,780USD90

Inspect the source

Entity
PROVECTUS BIOPHARMACEUTICALS, INC. / CIK 0000315545
Captured
2026-09-19T14:56:22.911Z
SEC response SHA-256
5c46f06a9f23badc21fb49ef63f53fb89ac39f7570babcbf8a64cddf67fb05d2

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000315545.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))